A carregar...
Publicação
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 653.99 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
Descrição
Palavras-chave
Influenza Vaccine Effectiveness VEBIS Primary Care Hospital Europe Investigação em Serviços de Saúde Estados de Saúde e de Doença Infecções Respiratórias Cuidados de Saúde
Contexto Educativo
Citação
Euro Surveill. 2024 Feb;29(8):2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089
Editora
European Centre for Disease Prevention and Control